Latest Market News

TPC Consolidated and Wollar Solar Holding have agreed to extend key deadlines in their acquisition scheme as they await crucial FIRB approval, pushing the timeline into early 2026.

WestStar Industrial’s subsidiary SIMPEC has landed a $115 million contract to expand residue filtration capacity at Alcoa’s Pinjarra Alumina Refinery, marking a key growth milestone.

Amplitude Energy has launched the retail component of its fully underwritten entitlement offer, aiming to raise approximately A$20 million to support key growth projects including the expansion of the East Coast Supply Project and the potential restart of Patricia Baleen.

Global X Management (AUS) Limited has released updated estimated distribution amounts for 12 of its ETFs listed on the ASX AQUA Market, covering the September 2025 period. The announcement includes key dates and confirms distribution reinvestment plan eligibility for all funds.

Rio Tinto Limited has updated its dividend reinvestment plan details, announcing a DRP share price of AUD 121.97 and an allocation date of 2 October 2025 for its fully franked interim dividend.

Variscan Mines has successfully completed the majority of the second tranche of its $2.5 million capital raise, issuing over 330 million shares and nearly 200 million options to support its zinc-lead project in Spain.

Southern Palladium has responded to an ASX price query denying undisclosed information behind its recent share price rise, instead pointing to positive commodity price trends and ongoing project developments.

RAM Essential Services Property Fund (REP) reports a Q1 FY26 distribution in line with guidance and reaffirms its full-year yield target while progressing its strategic transition to a healthcare-focused REIT.

Future Metals NL has appointed seasoned resources executive Keith Bowes as Managing Director and CEO, aiming to accelerate development of its flagship Panton and Eileen Bore projects.

Locksley Resources has completed its second tranche placement with Tribeca, significantly strengthening its cash reserves to support its U.S. mine-to-market ambitions.

Bio-Gene Technology Limited has addressed ASX concerns over the timing of its announcement on promising Flavocide efficacy data, confirming compliance with continuous disclosure rules after receiving final presentation materials from Purdue University.

OncoSil Medical has affirmed the materiality of the PANCOSIL Phase 1-2 trial results and detailed its compliance with ASX disclosure rules following the data presentation at CIRSE 2025.